CmaxInsight Market Intelligence: Market Research Reports

... clients within 1-2 Business Days. CmaxInsight’s, “G-Protein Coupled Receptor (GPCR) Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights ... companies Assess challenges and opportunities that influence G-Protein Coupled Receptor (GPCR) Agonist R&D Please note: Certain sections in the ...

... Business Days. CmaxInsight’s, “Growth Hormone (GH) Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... the client to understand the landscape of the Growth Hormone (GH) Agonist. Pipeline Covered: This section mentions all the promising ...

... 1-2 Business Days. CmaxInsight’s, “Growth Hormone Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Growth Hormone Antagonist. Pipeline Covered: This section mentions all the promising ...

... the clients within 1-2 Business Days. CmaxInsight’s, “Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators-Pipeline Intelligence, 2019”, report ... potential partners with progressing projects for Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators to enhance and ...

... Days. CmaxInsight’s, “Guanylate Cyclase-Coupled Receptor Activators-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... to understand the landscape of the Guanylate Cyclase-Coupled Receptor Activators. Pipeline Covered: This section mentions all the ...

... within 1-2 Business Days. CmaxInsight’s, “H1 Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MoA ... the client to understand the landscape of the H1 Antagonist. Pipeline Covered: This section mentions all the promising therapies ...

... 1-2 Business Days. CmaxInsight’s, “H 2 Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MoA ... the client to understand the landscape of the H 2 Antagonist. Pipeline Covered: This section mentions all the promising therapies in ...

... 1-2 Business Days. CmaxInsight’s, “H 3 Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MoA ... the client to understand the landscape of the H 3 Antagonist. Pipeline Covered: This section mentions all the promising therapies in ...

... 1-2 Business Days. CmaxInsight’s, “H 4 Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MoA ... the client to understand the landscape of the H 4 Antagonist. Pipeline Covered: This section mentions all the promising therapies in ...

... within 1-2 Business Days. CmaxInsight’s, “HDAC Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the HDAC Inhibitor. Pipeline Covered: This section mentions all the promising therapies ...

... clients within 1-2 Business Days. CmaxInsight’s, “Heat Shock Protein (Hsp) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence Heat Shock Protein (Hsp) Inhibitor R&D Please note: Certain sections in the ...

... coverage of MoA enables the client to understand the landscape of the Hedgehog Signaling Pathway Antagonist. Pipeline Covered: This section mentions all the promising therapies in different ...

... the clients within 1-2 Business Days. CmaxInsight’s, “Hepatitis C Virus (HCV) Protease Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... identifying potential partners with progressing projects for Hepatitis C Virus (HCV) Protease Inhibitor to enhance and expand business potential ...

... within 1-2 Business Days. CmaxInsight’s, “Hepcidin Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the Hepcidin Antagonist. Pipeline Covered: This section mentions all the promising ...

... 1-2 Business Days. CmaxInsight’s, “HIV Attachment Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the HIV Attachment Inhibitor. Pipeline Covered: This section mentions all the promising ...

... to the clients within 1-2 Business Days. CmaxInsight’s, “Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor-Pipeline Intelligence, 2019”, ... by identifying potential partners with progressing projects for Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor to enhance ...

... the clients within 1-2 Business Days. CmaxInsight’s, “Hypoxia Inducible Factor 1 (HIF-1) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... identifying potential partners with progressing projects for Hypoxia Inducible Factor 1 (HIF-1) Inhibitor to enhance and expand business potential ...

... clients within 1-2 Business Days. CmaxInsight’s, “Hypoxia Inducible Factor Prolyl-4-Hydroxylase (HIF-PH) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive ... potential partners with progressing projects for Hypoxia Inducible Factor Prolyl-4-Hydroxylase (HIF-PH) Inhibitor to enhance and expand business ...

... Business Days. CmaxInsight’s, “IkappaB Kinase (IKK) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... the client to understand the landscape of the IkappaB Kinase (IKK) Inhibitor. Pipeline Covered: This section mentions all the promising ...

... Business Days. CmaxInsight’s, “IL-6 Receptor Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... client to understand the landscape of the IL-6 Receptor Antagonist. Pipeline Covered: This section mentions all the promising therapies ...

... to the clients within 1-2 Business Days. CmaxInsight’s, “Inducible Nitric Oxide Synthase (iNOS or Type II NOS) Inhibitor-Pipeline Intelligence, 2019”, report ... by identifying potential partners with progressing projects for Inducible Nitric Oxide Synthase (iNOS or Type II NOS) Inhibitor to enhance and ...

... clients within 1-2 Business Days. CmaxInsight’s, “Inhibitor of Apoptosis (IAP) Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence Inhibitor of Apoptosis (IAP) Antagonist R&D Please note: Certain sections in the ...

... the clients within 1-2 Business Days. CmaxInsight’s, “Insulin Like Growth Factor (IGF) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... identifying potential partners with progressing projects for Insulin Like Growth Factor (IGF) Inhibitor to enhance and expand business potential ...

... delivered to the clients within 1-2 Business Days. CmaxInsight’s, “Insulin Like Growth Factor 1 (IGF-1) Activators-Pipeline Intelligence, 2019”, report provides ... by identifying potential partners with progressing projects for Insulin Like Growth Factor 1 (IGF-1) Activators to enhance and expand ...

... within 1-2 Business Days. CmaxInsight’s, “Integrase Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the Integrase Inhibitor. Pipeline Covered: This section mentions all the promising ...

... the clients within 1-2 Business Days. CmaxInsight’s, “Integrin Alpha 4beta1/Very Late Antigen-4 (VLA-4) Inhibitor-Pipeline Intelligence, 2019”, report provides ... identifying potential partners with progressing projects for Integrin Alpha 4beta1/Very Late Antigen-4 (VLA-4) Inhibitor to enhance and expand ...

... within 1-2 Business Days. CmaxInsight’s, “interleukin Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the interleukin Agonist. Pipeline Covered: This section mentions all the promising ...

... Business Days. CmaxInsight’s, “Interleukin-1 (IL-1) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... client to understand the landscape of the Interleukin-1 (IL-1) Inhibitor. Pipeline Covered: This section mentions all the promising ...

... coverage of MoA enables the client to understand the landscape of the Interleukin-10 (IL-10) Receptor Agonist. Pipeline Covered: This section mentions all the promising therapies in different ...

... Business Days. CmaxInsight’s, “Interleukin-12 (IL-12) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... client to understand the landscape of the Interleukin-12 (IL-12) Inhibitor. Pipeline Covered: This section mentions all the promising ...

... Business Days. CmaxInsight’s, “Interleukin-13 (IL-13) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... client to understand the landscape of the Interleukin-13 (IL-13) Inhibitor. Pipeline Covered: This section mentions all the promising ...

... Business Days. CmaxInsight’s, “Interleukin-17 (IL-17) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... client to understand the landscape of the Interleukin-17 (IL-17) Inhibitor. Pipeline Covered: This section mentions all the promising ...

... Business Days. CmaxInsight’s, “Interleukin-18 (IL-18) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... client to understand the landscape of the Interleukin-18 (IL-18) Inhibitor. Pipeline Covered: This section mentions all the promising ...

... Business Days. CmaxInsight’s, “Interleukin-2 (IL-2) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... client to understand the landscape of the Interleukin-2 (IL-2) Inhibitor. Pipeline Covered: This section mentions all the promising ...

... coverage of MoA enables the client to understand the landscape of the Interleukin-2 (IL-2) Receptor Agonist. Pipeline Covered: This section mentions all the promising therapies in different ...

... Business Days. CmaxInsight’s, “Interleukin-23 (IL-23) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... client to understand the landscape of the Interleukin-23 (IL-23) Inhibitor. Pipeline Covered: This section mentions all the promising ...

... Business Days. CmaxInsight’s, “Interleukin-4 (IL-4) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... client to understand the landscape of the Interleukin-4 (IL-4) Inhibitor. Pipeline Covered: This section mentions all the promising ...

... Business Days. CmaxInsight’s, “Interleukin-5 (IL-5) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... client to understand the landscape of the Interleukin-5 (IL-5) Inhibitor. Pipeline Covered: This section mentions all the promising ...

... Business Days. CmaxInsight’s, “Interleukin-8 (IL-8) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... client to understand the landscape of the Interleukin-8 (IL-8) Inhibitor. Pipeline Covered: This section mentions all the promising ...

... coverage of MoA enables the client to understand the landscape of the Ionotropic Glutamate Receptor Antagonist. Pipeline Covered: This section mentions all the promising therapies in different ...

... coverage of MoA enables the client to understand the landscape of the Isocitrate Dehydrogenase (IDH1) Inhibitor. Pipeline Covered: This section mentions all the promising therapies in different ...

... Business Days. CmaxInsight’s, “Janus Kinase (JAK) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... the client to understand the landscape of the Janus Kinase (JAK) Inhibitor. Pipeline Covered: This section mentions all the promising ...

... the clients within 1-2 Business Days. CmaxInsight’s, “Janus Kinase 1 (JAK1) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence Janus Kinase 1 (JAK1) Inhibitor R&D Please note: Certain sections in the report ...

... the clients within 1-2 Business Days. CmaxInsight’s, “Janus Kinase 3 (JAK3) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence Janus Kinase 3 (JAK3) Inhibitor R&D Please note: Certain sections in the report ...

... 1-2 Business Days. CmaxInsight’s, “Kainate Receptor Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Kainate Receptor Antagonist. Pipeline Covered: This section mentions all the promising ...

... within 1-2 Business Days. CmaxInsight’s, “Kallikrein Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ... the client to understand the landscape of the Kallikrein Inhibitor. Pipeline Covered: This section mentions all the promising ...

... within 1-2 Business Days. CmaxInsight’s, “Kappa Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the Kappa Antagonist. Pipeline Covered: This section mentions all the promising ...

... Days. CmaxInsight’s, “Kv1.3/1.5 Potassium Channel Blockers-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... client to understand the landscape of the Kv1.3/1.5 Potassium Channel Blockers. Pipeline Covered: This section mentions all the promising ...

... Days. CmaxInsight’s, “Kv1.3 Potassium Channel Blockers-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... the client to understand the landscape of the Kv1.3 Potassium Channel Blockers. Pipeline Covered: This section mentions all the promising ...

... within 1-2 Business Days. CmaxInsight’s, “LAG-3 Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the LAG-3 Antagonist. Pipeline Covered: This section mentions all the promising ...